ESTRO 2022 - Abstract Book

S320

Abstract book

ESTRO 2022

Results 509 patients were included, training = 302, validation = 75, test = 132. Median follow-up was 762 days. Train-validation and external test set mean age was 74 and 71 respectively. Recurrence and RFS rates at 2 years were 36.3% vs 30.3%, and 48% vs 43.9% respectively. For recurrence Principal Component Analysis followed by an ensemble of Partial Least Squares (PLS), K-Nearest Neighbours and Elastic-net was the best performing model. For RFS, Pearson correlation with PLS was the best performing model. The respective validation and test set AUCs and 95% confidence intervals are shown in Table 1. Our model had superior AUC to the TNM model in both validation and test sets for predicting RFS. For recurrence, AUC was superior to the TNM stage model in the validation set and similar in the test set. Kaplan Meier curves showed marked separation with significant log-rank tests (Figure 1).

Conclusion We present validated and externally tested recurrence risk-stratification models that use routinely available radiotherapy data. Such models could be integrated into the radiotherapy workflow to inform personalised surveillance at the point of treatment for patients with NSCLC.

MO-0385 Added value of MRI radiomics to predict pathological status of prostate cancer patients

G. Marvaso 1 , M. Pepa 2 , L.J. Isaksson 2 , P.E. Summers 3 , M. Zaffaroni 2 , M.G. Vincini 2 , G. Corrao 1 , G.C. Mazzola 1 , M. Rotondi 1 , S. Raimondi 4 , S. Gandini 4 , S. Volpe 1 , Z. Haron 5 , S. Alessi 3 , P. Pricolo 3 , F.A. Mistretta 6 , S. Luzzago 6 , F. Cattani 7 , G. Musi 8 , O. De Cobelli 8 , M. Cremonesi 9 , R. Orecchia 10 , G. Petralia 11 , B.A. Jereczek-Fossa 1 1 University of Milan; IEO European Institute of Oncology IRCCS, Department of Oncology and Hemato-Oncology; Division of Radiation Oncology, Milan, Italy; 2 IEO European Institute of Oncology IRCCS, Division of Radiation Oncology, Milan, Italy; 3 IEO European Institute of Oncology IRCCS, Division of Radiology, Milan, Italy; 4 IEO European Institute of Oncology IRCCS, Department of Experimental Oncology, Milan, Italy; 5 National Cancer Institute, Radiology Department, Putrajaya, Malaysia; 6 IEO European Institute of Oncology IRCCS, Division of Urology, Milan, Italy; 7 IEO European Institute of Oncology IRCCS, Unit of Medical Physics, Milan, Italy; 8 University of Milan; IEO European Institute of Oncology IRCCS, Department of Oncology and Hemato-Oncology; Division of Urology, Milan, Italy; 9 IEO European Institute of Oncology IRCCS, Radiation Research Unit, Milan, Italy; 10 IEO European Institute of Oncology IRCCS, Scientific Directorate, Milan, Italy; 11 University of Milan; IEO European Institute of Oncology IRCCS, Department of Oncology and Hemato-Oncology; Division of Radiology, Milan, Italy